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Primary sclerosing cholangitis (PSC) is an idiopathic, chronic
cholestatic disease of possible autoimmune origin that is char-
acterized by diffuse cholangitis and progressive ﬁbrosis of the
extra- and intrahepatic bile ducts. PSC typically manifests inance cholangiopancreatogra-
s
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sevier B.V.Open access under the fourth or ﬁfth decade. There is a distinct male preponder-
ance (1).
The classic imaging ﬁndings of PSC include multifocal stric-
tures, ectasias, ductal wall thickening, and irregular beading of
the intra- and extrahepatic bile ducts (2,3).
A strong association with the inﬂammatory bowel disease,
especially ulcerative colitis, is noted (70% of cases) (4). The
rate of progression is unpredictable, with up to 49% of symp-
tomatic patients eventually developing biliary cirrhosis and li-
ver failure. Treatment is usually palliative and includes medical
therapy with orally administered agents such as ursodiol (urso-
deoxycholic acid) or endoscopic or percutaneous mechanical
dilation of dominant strictures. Currently, orthotopic liver
transplantation is the only curative therapy for PSC (5).
The chronic inﬂammation of PSC predisposes to the devel-
opment of cholangiocarcinoma (CCA), the most dreaded com-
plication of PSC (1). CCA develops in 10% of patients with
PSC. The incidence of CCA in patients with PSC is 0.6–1.5%
per year, with the highest incidence in the ﬁrst 2 years after
diagnosis of PSC. Patients with PSC develop CCA approxi-
mately 2–3 decades earlier than patients without PSC (6).
352 M. Eid, K.A. MatrawyCholangiographic features that suggest cholangiocarci-
noma include irregular high grade ductal narrowing with
shouldered margins, rapid progression of strictures, marked
ductal dilatation proximal to strictures, and polypoid lesions.
Secondary sclerosing and nonsclerosing processes can mimic
primary sclerosing cholangitis at cholangiography (7).
In a small percentage of patients, focal segmental involve-
ment of PSC manifesting as a focal short-segment stricture
without the classic imaging ﬁndings makes it difﬁcult to distin-
guish from the periductal-inﬁltrating type of CCA (8).
Secondary sclerosing cholangitis syndromes are a heteroge-
neous group of chronic cholestatic disorders that are morpholog-
ically similar toPSCbut result fromdistinct pathologic processes.
The wide spectrumof secondary sclerosing cholangitis entities in-
cludes recurrent pyogenic cholangitis, acquired immunodeﬁ-
ciency syndrome (AIDS) cholangiopathy, autoimmune
pancreatitis, hepatic inﬂammatory pseudotumor, eosinophilic
cholangitis, portal biliopathy, and ischemic cholangiopathy (9).
Although percutaneous biopsy specimens may demonstrate
ﬁndings that are suggestive of PSC, such as numerous eosino-
phils in the periportal parenchyma, periductal ﬁbrosis, and
ductopenia, there is no histologic feature that is pathogno-
monic of PSC (10). Likewise, the results of biochemical analy-
sis are nonspeciﬁc; they reveal elevated alkaline phosphatase
and/or bilirubin levels, which can be seen in a variety of chole-
static processes in addition to PSC (11).
The diagnosis of PSC is usually established with endoscopic
retrograde cholangiopancreatography (ERCP) and less often
with percutaneous transhepatic cholangiography; these studies
demonstrate multiple segmental strictures, mural irregularities,
and diverticula that are characteristic of PSC. Although ERCP
and percutaneous transhepatic cholangiography provide high-
quality images of the biliary tract, both are invasive procedures
that are associated with risks of sepsis and hemorrhage. ERCP
is also associated with risks of pancreatitis and bowel perfora-
tion and has been shown to result in progression of cholestasis
in patients with advanced PSC (12).
Magnetic resonance cholangiopancreatography (MRCP) is
a relatively new, noninvasive cholangiographic technique that
is comparable with invasive endoscopic retrograde cholangio-
pancreatography (ERCP) in the detection and characterization
of extrahepatic bile duct abnormalities. The role of MRCP in
evaluation of the intrahepatic bile ducts, especially in patients
with primary or secondary sclerosing cholangitis, is under
investigation (7).
Although ERCP is still the standard of reference for imag-
ing the pancreaticobiliary system, MRCP has some advantages
over ERCP.
Speciﬁcally, MRCP (a) is noninvasive; (b) is cheaper; (c)
uses no ionizing radiation; (d) requires no anesthesia; (e) is less
operator dependent; (f) better demonstrates ducts proximal to
an obstruction or tight stenosis; and (g) when combined with
conventional T1- and T2-weighted sequences, allows anatomic
imaging of extraductal disease. However, MRCP provides less
spatial resolution than ERCP, thereby decreasing the sensitiv-
ity to peripheral ductal abnormalities. In addition, the periph-
eral ducts may not be visualized because imaging is performed
in the physiologic, nondistended state. The main criticism of
MRCP is that appropriate care may be delayed in patientswho need therapeutic endoscopic or percutaneous intervention
of obstructing bile duct lesions (7).
1.1. Principles of MR cholangiopancreatography
At MR cholangiopancreatography, the bile within the biliary
tree is imaged with heavily T2-weighted sequences. The se-
quences are heavily T2 weighted with use of long echo times
in the range of 300–1000 ms, such that only tissues or ﬂuid
with prolonged transverse relaxation time (T2) retain signal.
These tissues and ﬂuid are seen as hyperintense structures.
The background soft tissues with shorter T2 do not retain sig-
niﬁcant signal long enough in a sequence with prolonged echo
time and are, therefore, suppressed. Blood vessels are not seen,
since ﬂowing blood does not produce any signal on these
images (13).1.2. Types of sequences used
1.2.1. Fast spin-echo (turbo spin-echo) sequence
With the fast spin-echo (FSE) (turbo spin-echo [TSE]) se-
quence, a 90 radiofrequency (RF) pulse is followed by a train
of 180 RF pulses. The number of 180 pulses is called the echo
train length (ETL) or turbo factor. The speed of acquisition in-
creases with an increase in ETL. For the purposes of MR chol-
angiopancreatography, FSE imaging is performed with a long
ETL, repetition time, and echo time (>250 ms) (14).
A long ETL is well suited for the type of long echo-time
acquisition required for MR cholangiopancreatography. FSE
imaging can be performed with a breath hold or with free
breathing with the use of respiratory gating or a navigator
technique (13).
It can be performed as a two-dimensional (2D) sequence
with a slab thickness of 2–7 cm or as a three-dimensional
(3D) sequence with thinner sections. The resultant data can
then be reconstructed into cholangiographic images with a
maximum-intensity-projection (MIP) technique (14).
Fast recovery FSE (FRFSE; GE Medical Systems, Wauke-
sha, Wis), RESTORE (Siemens Medical Solutions, Forch-
heim, Germany), and driven equilibrium FSE (DRIVE;
Philips Medical Systems, Best, the Netherlands) sequences
are modiﬁed FSE sequences in which a 90 RF pulse is used
at the end of the ETL to get the magnetization immediately
in longitudinal plane, thereby reducing repetition time (13).
Single-shot FSE (TSE) sequence single-shot FSE (SSFSE,
GE Medical Systems), half-Fourier single-shot TSE (HASTE,
Siemens), and single-shot TSE (SSTSE, Philips) sequences are
FSE sequences in which just more than one half of k-space is
ﬁlled, thus reducing scanning time signiﬁcantly. All of the re-
quired k-space lines (phase-encoding steps) are ﬁlled in a single
repetition time; hence the name ‘‘single-shot.’’ Acquisition
times are in seconds, with reasonably good spatial resolution
(15). SSFSE imaging has a higher signal-to-noise ratio
(SNR) than does FSE imaging as a result of less motion arti-
fact producing noise (14).
Limitations of SSFSE imaging include image blur induced
by long ETLs, ﬂow artifacts, and problems with saturation
of adjacent sections. Echo times typically range between 300
Figure 1 Coronal 3D-T2 MRI revealed characteristic segmental
dilatation of the intrahepatic biliary radicles, separated by
multiple strictures. Note the pancreatic duct dilatation resulting
from associated autoimmune pancreatitis.
Figure 2 Coronal 3D-T2 MRI revealed characteristic segmental
dilatation of the intrahepatic biliary radicles, separated by multiple
strictures (arrows). Note the stricture (asterisk) affecting the CBD.
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hold or with respiratory triggering, and good-quality images
can be obtained, even with quiet breathing (15).
1.2.2. Other sequences
Fast gradient-echo sequences such as balanced fully refocused
steady-state sequences (true fast imaging with steady-state pre-
cession, fast imaging employing steady-state acquisition, bal-
anced fast ﬁeld echo) show the biliary tree well, with
excellent SNR and good spatial resolution. These sequences
can be performed with a breath hold or with quiet breathing
and may show ducts reasonably well when other sequences fail
to do so because of motion artifacts. One limitation, however,
is the fact that blood vessels are seen as bright structures,
which may make it difﬁcult to differentiate them from bile
ducts (13).
Diagnostic criteria for PSC include (a) typical cholangio-
graphic abnormalities; (b) appropriate clinical, biochemical,
and hepatic histologic ﬁndings; and (c) the exclusion of sec-
ondary causes of sclerosing cholangitis. Cholangiographic
ﬁndings usually include multifocal, intrahepatic bile duct stric-
tures alternating with normal-caliber ducts, which sometimes
produce a beaded appearance (16).
Although patients may be asymptomatic, 75% have pro-
gressive fatigue, pruritus, or jaundice (17). At biochemical
analysis, levels of serum bilirubin and alkaline phosphatase
are increased in most patients, with a mean increase in the
alkaline phosphatase level to three times the upper limit of nor-
mal Because histologic examination of the liver shows nonspe-
ciﬁc inﬂammatory ﬁbrosis of the portal triads and a paucity of
bile ducts, histologic analysis is used only for conﬁrmation of a
suspected diagnosis of PSC (17,18).
Before the diagnosis of PSC is established, secondary scle-
rosing and nonsclerosing processes that mimic PSC at cholan-
giography must be excluded (16).
The cholangiographic ﬁndings in PSC depend on the stage
of the disease process. Early in the course of the disease, ran-
domly distributed, short (1–2 mm), annular intrahepatic stric-
tures alternating with normal or slightly dilated segments
produce a beaded appearance. Strictures usually occur at the
bifurcation of ducts and are out of proportion to upstream
ductal dilatation. The peripheral ducts should extend to the
periphery of the liver and form acute angles with the central
ducts. As the ﬁbrosing process worsens, strictures increase
and the ducts become obliterated, and the peripheral ducts
cannot be visualized to the periphery of the liver at ERCP,
producing a ‘‘pruned tree’’ appearance (16).
In addition, the acute angles formed with the central ducts
become more obtuse.
With further progression, strictures of the central ducts pre-
vent peripheral ductal opaciﬁcation at ERCP. The key cholan-
giographic features of PSC are randomly distributed annular
strictures out of proportion to upstream dilatation, which
probably reﬂect periductal inﬂammation and ﬁbrosis that pre-
vent the ducts from dilating (17,18).
If the ducts in a case simulating PSC are dilated, one should
consider other sclerosing ductal processes such as ascending
cholangitis or PSC complicated by cholangiocarcinoma. Other
cholangiographic ﬁndings include webs, diverticula, and
stones. A web is a focal, 1–2-mm thick area of incomplete cir-
cumferential narrowing; a diverticulum is a focal, eccentric,
saccular dilatation of the bile duct. These two ﬁndings mayrepresent manifestations of the same abnormality because a
web may transform into a diverticulum with an increase in
intraductal pressure during conventional cholangiography
(19). Diverticula and webs are not pathognomonic for PSC
and can be seen in other inﬂammatory and traumatic processes
(19). Up to 27% of patients with PSC have diverticula. Pri-
mary pigmented stones occur in 30% of patients with PSC sec-
ondary to bile stasis (19).
2. Materials and methods
Magnetic resonance cholangiopancreatography (MRCP) was
done for the included patients using a 1.5-T closed MR unit
(Avanto, Siemens) with a circularly polarized; phased-array
body coil was used in all cases.
Antiperistaltic agents and oral contrast material were not
used, and the patients did not fast prior to the examination.
354 M. Eid, K.A. MatrawyAll the patients were examined by using half-Fourier rapid
acquisition with relaxation enhancement (RARE) MR cholan-
giographic sequences.3. Results
The study included 20 patients (12 women and 8 men) age ran-
ged from 29 to 70 years.
All the patients presented with obstructive jaundice and
abdominal pain.
In 3 patients cholangiocarcinoma was seen superadded on
primary sclerosing cholangitis (PSC).
Two patients were diagnosed as ulcerative colitis.Figure 4 (A) Axial T2W image shows scattered periportal patches
dilatations of the intrahepatic biliary radicles, as well as the CBD. (C
associated with PSC.
Figure 3 (A) Axial T2W image shows a hepatic hyperintense mass w
strictures and dilatations of the intrahepatic biliary radicles, away fro3.1. Case 1 (PSC)
A 23 years old female, suffering from ulcerative colitis pre-
sented with obstructive jaundice and abdominal pain.
Fig. 1: Coronal 3D-T2 MRI revealed characteristic segmental
dilatationof the intrahepatic biliary radicles, separatedbymulti-
ple strictures. Note the pancreatic duct dilatation resulting from
associated autoimmune pancreatitis.
3.2. Case 2 (PSC)
A 58 years old female, suffering from obstructive jaundice.of hyperintensity. (B) MRCP shows the segmental strictures and
) Sonography reveals mild diffuse GB wall thickening, a feature
ith segmental biliary dilatation. (B) MRCP shows the segmental
m the mass.
Primary Sclerosing Cholangitis: Evaluation with MRCP 355Fig. 2: Coronal 3D-T2 MRI revealed characteristic segmen-
tal dilatation of the intrahepatic biliary radicles, separated
by multiple strictures (arrows). Note the stricture (asterisk)
affecting the CBD.3.3. Case 3 (PSC and CCA)
A 60 years old female, suffering from obstructive jaundice.
 Fig. 3(A): Axial T2W image shows a hepatic hyperintense
mass with segmental biliary dilatation.
 Fig. 3(B): MRCP shows the segmental strictures and dilata-
tions of the intrahepatic biliary radicles, away from themass.3.4. Case 4 (PSC patches)
A 60 years old female, suffering from obstructive jaundice.
 Fig. 4(A): Axial T2W image shows scattered periportal
patches of hyperintensity.
 Fig. 4(B): MRCP shows the segmental strictures and dilata-
tions of the intrahepatic biliary radicles, as well as the CBD.
 Fig. 4(C): Sonography reveals mild diffuse GB wall thicken-
ing, a feature associated with PSC.4. Discussion
MRCPperformed with the single-shot fast spine echo technique
is a promising, noninvasive alternative to more invasive direct
cholangiography for evaluating the intrahepatic and extrahe-
patic bile ducts in patients with sclerosing cholangitis (7).
MRCP has high sensitivity and very high speciﬁcity for the
diagnosis of PSC. In many cases of suspected PSC, MRCP is
sufﬁcient for diagnosis, and, thus, the risks associated with
ERCP can be avoided (21).
MRCP enabled conﬁrmation of PSC; in patients with low
pretest probabilities, MRCP enabled exclusion of PSC (21).
High-quality magnetic resonance (MR) cholangiopancrea-
tographic images are difﬁcult to obtain in children due to the
small caliber of the pediatric bile ducts and motion artifacts.
However, there has been ongoing improvement in image qual-
ity, thanks to better coil technology, increased speed of acqui-
sition, reﬁnement in respiratory compensation techniques, and
newer sequences. Heavily T2-weighted fast spin-echo (FSE)
and single-shot FSE MR imaging sequences with long echo-
times are used to image the biliary and pancreatic ducts (13).
MR cholangiography was found to be accurate in detecting
PSC and in deﬁning the extent of disease. In the detection of
PSC, the sensitivities were 88% and 85%; speciﬁcities, 97%
and 92% (20).
Sixty percent to 80% of patients with PSC have associated
inﬂammatory bowel disease, especially ulcerative colitis (1).
Cholangiocarcinoma is the second most common primary
malignant hepatobiliary neoplasm, accounting for approxi-
mately 15% of liver cancers. Diagnosis of cholangiocarcinoma
is challenging and the prognosis is uniformly poor, with recur-
rence rates of 60–90% after surgical resection (8).
The chronic inﬂammation of PSC predisposes to the devel-
opment of CCA, the most dreaded complication of PSC (1).
CCA develops in 10% of patients with PSC. The incidence
of CCA in patients with PSC is 0.6–1.5% per year, with thehighest incidence in the ﬁrst 2 years after diagnosis of PSC. Pa-
tients with PSC develop CCA approximately 2–3 decades ear-
lier than patients without PSC (6).
In our work we concluded thatMRCP is a noninvasive tech-
nique that is comparable with ERCP in the detection and local-
ization of bile duct obstruction and choledocholithiasis.
MRCPhas some advantages over ERCP. Speciﬁcally,MRCP
is non invasive, cheaper; uses no ionizing radiation; requires no
anesthesia; less operator dependent; better demonstrating ducts
proximal to an obstruction or tight stenosis; and when combined
with conventional T1- and T2-weighted sequences, allows ana-
tomic imaging of extraductal disease. However, MRCP provides
less spatial resolution thanERCP, therebydecreasing the sensitiv-
ity to peripheral ductal abnormalities.
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